Redefining peptide therapeutics with semaglutide
Crossref DOI link: https://doi.org/10.1038/s41557-023-01434-4
Published Online: 2024-02-06
Published Print: 2024-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kruse, Thomas http://orcid.org/0000-0002-5756-753X
Østergaard, Søren http://orcid.org/0000-0002-9415-3352
Text and Data Mining valid from 2024-02-01
Version of Record valid from 2024-02-01
Article History
First Online: 6 February 2024
Competing interests
: T.K. and S.O. are employees and shareholders of Novo Nordisk.